MedPath

A Study of Ginsenoside H Dripping Pills for Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 2
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
Registration Number
NCT02714608
Lead Sponsor
Tasly Pharmaceuticals, Inc.
Brief Summary

Ginsenoside H dripping pills is a kind of traditional Chinese medicine(TCM), This study is being conducted to evaluate the efficacy and safety of ginsenoside H dripping pills in patients with advanced (stage ⅢB/Ⅳ) Non-small Cell Lung Cancer (Syndrome Of Qi-Deficiency) and explore the optimal dosage

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
144
Inclusion Criteria
  1. Pathologically or cytologically proven stage IIIB/IV NSCLC with a measurable lesions (including postoperative recurrence or metastasis)
  2. The patients who can not be treated by surgical resection, conventional radiotherapy and chemotherapy or molecular targeted drugs treatment failure, not willing to accept, or intolerance to radiotherapy and chemotherapy or molecular targeted therapy.
  3. The TCM Syndrome diagnosis of Qi-Deficiency.
  4. Aged 18-75 years, both male and female.
  5. ECOG performance status 0-2.
  6. Expected to survive more than 3 months.
  7. Joined in the test voluntarily and signed the Informed consent by GCP regulation.
Exclusion Criteria
  1. Liver and kidney damage(TBIL、ALT、AST is higher than the limit of normal value of 1.5 times, abnormal Cr).
  2. Patients with significant cachexia.
  3. Untreated symptomatic brain metastases.

4 .Allergic constitution, or for a variety of drug allergy.

5 .Combined with severe cardiovascular, hepatic, renal disease , pregnancy or breast-feeding women, psychopath.

  1. Participated in other clinical trial within 3 months.

  2. Treated by chemotherapy, radiotherapy or targeted therapy within 4 weeks.

  3. Possible to be treated by chemotherapy, radiotherapy or targeted therapy during the study.

  4. Not fit for the clinical trial judged by the investigator.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Ginsenoside H dripping pills+PlaceboGinsenoside H dripping pills+PlaceboDrug: Ginsenoside H dripping pills ,Placebo. Dosage form:pill. Dosage :20pills ( ginsenoside H dripping pills 10 pills and placebo 10 pills). Frequency:two times per day. Duration: until disease progression or death.
Ginsenoside H dripping pillsGinsenoside H dripping pillsDrug: Ginsenoside H dripping pills. Dosage form:pill. Dosage :20pills ( only ginsenoside H dripping pills). Frequency:two times per day. Duration: until disease progression or death.
PlaceboPlaceboDrug: Placebo. Dosage form:pill. Dosage :20pills ( only placebo ). Frequency:two times per day. Duration: until disease progression or death.
Primary Outcome Measures
NameTimeMethod
Progression-free survival (PFS)through study completion, an average of 1 year

Evaluate progression free survival (PFS) in the 3 groups : 0 , every 8 weeks and the end of treatment

Secondary Outcome Measures
NameTimeMethod
Overall Survival (OS)through study completion, an average of 1 year

Evaluate overall survival (OS) in the 3 groups

Symptoms scores of TCMthrough study completion, an average of 1 year

0 , every 4 weeks and the end of treatment

Time to progression(TTP)through study completion, an average of 1 year

Evaluate time to progression(TTP) in the 3 groups

Quality of Lifethrough study completion, an average of 1 year

\[0 , every 4 weeks and the end of treatment\] To determine the quality of life by using the European Organisation of Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) scales.

Cancer-related fatiguethrough study completion, an average of 1 year

Evaluate the fatigue degree in the 3 groups using the Chinese version of Brief Fatigue Index (BFI-C): 0 , every 4 weeks and the end of treatment

Trial Locations

Locations (9)

Jing'an District Centre Hospital of Shanghai

🇨🇳

Shang Hai, Shanghai, China

Guangdong Provincial Hospital of TCM

🇨🇳

Guang Zhou, Guangdong, China

Jiangsu Provincial Hospital of Integrated Chinese Traditional and Western Medicine

🇨🇳

Nan Jing, Jiangsu, China

Shuguang Hospital Affiliated with Shanghai University of TCM

🇨🇳

Shang Hai, Shanghai, China

West China Hospital ,Sichuan University

🇨🇳

Cheng Du, Sichuan, China

The Second People's Hospital of Yibin

🇨🇳

Yibin, Sichuan, China

The First Affiliated Hospital of Guangzhou University of TCM

🇨🇳

Guang Zhou, Guangdong, China

Tianjin People's Hospital

🇨🇳

Tian Jin, Tianjin, China

Hangzhou First People's Hospital

🇨🇳

Hang Zhou, Zhejiang, China

© Copyright 2025. All Rights Reserved by MedPath